PSMA-PET/CT-Based Stereotactic Body Radiotherapy (SBRT) in the Treatment of Uncomplicated Non-Spinal Bone Oligometastases from Prostate Cancer
Background and purpose: Stereotactic body radiotherapy (SBRT) has a consolidated role in the treatment of bone oligometastases from prostate cancer (PCa). While the evidence for spinal oligometastases SBRT was robust, its role in non-spinal-bone metastases (NSBM) is not standardized. In fact, there...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/10/2800 |
| _version_ | 1797600701169270784 |
|---|---|
| author | Edoardo Pastorello Luca Nicosia Francesco Cuccia Laura Olivari Matilde Fiorini Niccolò Giaj Levra Rosario Mazzola Francesco Ricchetti Michele Rigo Paolo Ravelli Salvatore D’Alessandro Matteo Salgarello Ruggero Ruggieri Filippo Alongi |
| author_facet | Edoardo Pastorello Luca Nicosia Francesco Cuccia Laura Olivari Matilde Fiorini Niccolò Giaj Levra Rosario Mazzola Francesco Ricchetti Michele Rigo Paolo Ravelli Salvatore D’Alessandro Matteo Salgarello Ruggero Ruggieri Filippo Alongi |
| author_sort | Edoardo Pastorello |
| collection | DOAJ |
| description | Background and purpose: Stereotactic body radiotherapy (SBRT) has a consolidated role in the treatment of bone oligometastases from prostate cancer (PCa). While the evidence for spinal oligometastases SBRT was robust, its role in non-spinal-bone metastases (NSBM) is not standardized. In fact, there was no clear consensus about dose and target definition in this setting. The aim of our study was to evaluate efficacy, toxicity, and the pattern of relapse in SBRT delivered to NSBM from PCa. Materials and methods: From 2016 to 2021, we treated a series of oligo-NSBM from PCa with <sup>68</sup>Ga-PSMA PET/CT-guided SBRT. The primary endpoint was local progression-free survival (LPFS). The secondary endpoints were toxicity, the pattern of intraosseous relapse, distant progression-free survival (DPFS), polimetastases-free survival (PMFS), and overall survival (OS). Results: a total of 150 NSBM in 95 patients were treated with 30–35 Gy in five fractions. With a median follow-up of 26 months, 1- and 3 years LPFS was 96.3% and 89%, respectively. A biologically effective dose (BED) ≥ 198 Gy was correlated with improved LPFS (<i>p</i> = 0.007). Intraosseous relapse occurred in eight (5.3%) cases. Oligorecurrent disease was associated with a better PMFS compared to de novo oligometastatic disease (<i>p</i> = 0.001) and oligoprogressive patients (<i>p</i> = 0.007). No grade ≥ 3 toxicity occurred. Conclusion: SBRT is a safe and effective tool for NSBM from PCa in the oligometastatic setting. Intraosseous relapse was a relatively rare event. Predictive factors of the improved outcomes were defined. |
| first_indexed | 2024-03-11T03:51:35Z |
| format | Article |
| id | doaj.art-4d3e5649b97b4c538c9f1eeba315e119 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T03:51:35Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-4d3e5649b97b4c538c9f1eeba315e1192023-11-18T00:49:11ZengMDPI AGCancers2072-66942023-05-011510280010.3390/cancers15102800PSMA-PET/CT-Based Stereotactic Body Radiotherapy (SBRT) in the Treatment of Uncomplicated Non-Spinal Bone Oligometastases from Prostate CancerEdoardo Pastorello0Luca Nicosia1Francesco Cuccia2Laura Olivari3Matilde Fiorini4Niccolò Giaj Levra5Rosario Mazzola6Francesco Ricchetti7Michele Rigo8Paolo Ravelli9Salvatore D’Alessandro10Matteo Salgarello11Ruggero Ruggieri12Filippo Alongi13Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, 37024 Negrar, ItalyAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, 37024 Negrar, ItalyFrancesco Cuccia, Radiotherapy Unit, ARNAS Civico Hospital, 90127 Palermo, ItalyNuclear Medicine Unit, IRCCS Ospedale Sacro Cuore Don Calabria, 37024 Negrar, ItalyAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, 37024 Negrar, ItalyAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, 37024 Negrar, ItalyAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, 37024 Negrar, ItalyAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, 37024 Negrar, ItalyAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, 37024 Negrar, ItalyAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, 37024 Negrar, ItalyAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, 37024 Negrar, ItalyNuclear Medicine Unit, IRCCS Ospedale Sacro Cuore Don Calabria, 37024 Negrar, ItalyAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, 37024 Negrar, ItalyAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, 37024 Negrar, ItalyBackground and purpose: Stereotactic body radiotherapy (SBRT) has a consolidated role in the treatment of bone oligometastases from prostate cancer (PCa). While the evidence for spinal oligometastases SBRT was robust, its role in non-spinal-bone metastases (NSBM) is not standardized. In fact, there was no clear consensus about dose and target definition in this setting. The aim of our study was to evaluate efficacy, toxicity, and the pattern of relapse in SBRT delivered to NSBM from PCa. Materials and methods: From 2016 to 2021, we treated a series of oligo-NSBM from PCa with <sup>68</sup>Ga-PSMA PET/CT-guided SBRT. The primary endpoint was local progression-free survival (LPFS). The secondary endpoints were toxicity, the pattern of intraosseous relapse, distant progression-free survival (DPFS), polimetastases-free survival (PMFS), and overall survival (OS). Results: a total of 150 NSBM in 95 patients were treated with 30–35 Gy in five fractions. With a median follow-up of 26 months, 1- and 3 years LPFS was 96.3% and 89%, respectively. A biologically effective dose (BED) ≥ 198 Gy was correlated with improved LPFS (<i>p</i> = 0.007). Intraosseous relapse occurred in eight (5.3%) cases. Oligorecurrent disease was associated with a better PMFS compared to de novo oligometastatic disease (<i>p</i> = 0.001) and oligoprogressive patients (<i>p</i> = 0.007). No grade ≥ 3 toxicity occurred. Conclusion: SBRT is a safe and effective tool for NSBM from PCa in the oligometastatic setting. Intraosseous relapse was a relatively rare event. Predictive factors of the improved outcomes were defined.https://www.mdpi.com/2072-6694/15/10/2800non-spinal bone metastasesSBRTstereotactic body radiotherapySABRPSMA PET/CToligometastases |
| spellingShingle | Edoardo Pastorello Luca Nicosia Francesco Cuccia Laura Olivari Matilde Fiorini Niccolò Giaj Levra Rosario Mazzola Francesco Ricchetti Michele Rigo Paolo Ravelli Salvatore D’Alessandro Matteo Salgarello Ruggero Ruggieri Filippo Alongi PSMA-PET/CT-Based Stereotactic Body Radiotherapy (SBRT) in the Treatment of Uncomplicated Non-Spinal Bone Oligometastases from Prostate Cancer Cancers non-spinal bone metastases SBRT stereotactic body radiotherapy SABR PSMA PET/CT oligometastases |
| title | PSMA-PET/CT-Based Stereotactic Body Radiotherapy (SBRT) in the Treatment of Uncomplicated Non-Spinal Bone Oligometastases from Prostate Cancer |
| title_full | PSMA-PET/CT-Based Stereotactic Body Radiotherapy (SBRT) in the Treatment of Uncomplicated Non-Spinal Bone Oligometastases from Prostate Cancer |
| title_fullStr | PSMA-PET/CT-Based Stereotactic Body Radiotherapy (SBRT) in the Treatment of Uncomplicated Non-Spinal Bone Oligometastases from Prostate Cancer |
| title_full_unstemmed | PSMA-PET/CT-Based Stereotactic Body Radiotherapy (SBRT) in the Treatment of Uncomplicated Non-Spinal Bone Oligometastases from Prostate Cancer |
| title_short | PSMA-PET/CT-Based Stereotactic Body Radiotherapy (SBRT) in the Treatment of Uncomplicated Non-Spinal Bone Oligometastases from Prostate Cancer |
| title_sort | psma pet ct based stereotactic body radiotherapy sbrt in the treatment of uncomplicated non spinal bone oligometastases from prostate cancer |
| topic | non-spinal bone metastases SBRT stereotactic body radiotherapy SABR PSMA PET/CT oligometastases |
| url | https://www.mdpi.com/2072-6694/15/10/2800 |
| work_keys_str_mv | AT edoardopastorello psmapetctbasedstereotacticbodyradiotherapysbrtinthetreatmentofuncomplicatednonspinalboneoligometastasesfromprostatecancer AT lucanicosia psmapetctbasedstereotacticbodyradiotherapysbrtinthetreatmentofuncomplicatednonspinalboneoligometastasesfromprostatecancer AT francescocuccia psmapetctbasedstereotacticbodyradiotherapysbrtinthetreatmentofuncomplicatednonspinalboneoligometastasesfromprostatecancer AT lauraolivari psmapetctbasedstereotacticbodyradiotherapysbrtinthetreatmentofuncomplicatednonspinalboneoligometastasesfromprostatecancer AT matildefiorini psmapetctbasedstereotacticbodyradiotherapysbrtinthetreatmentofuncomplicatednonspinalboneoligometastasesfromprostatecancer AT niccologiajlevra psmapetctbasedstereotacticbodyradiotherapysbrtinthetreatmentofuncomplicatednonspinalboneoligometastasesfromprostatecancer AT rosariomazzola psmapetctbasedstereotacticbodyradiotherapysbrtinthetreatmentofuncomplicatednonspinalboneoligometastasesfromprostatecancer AT francescoricchetti psmapetctbasedstereotacticbodyradiotherapysbrtinthetreatmentofuncomplicatednonspinalboneoligometastasesfromprostatecancer AT michelerigo psmapetctbasedstereotacticbodyradiotherapysbrtinthetreatmentofuncomplicatednonspinalboneoligometastasesfromprostatecancer AT paoloravelli psmapetctbasedstereotacticbodyradiotherapysbrtinthetreatmentofuncomplicatednonspinalboneoligometastasesfromprostatecancer AT salvatoredalessandro psmapetctbasedstereotacticbodyradiotherapysbrtinthetreatmentofuncomplicatednonspinalboneoligometastasesfromprostatecancer AT matteosalgarello psmapetctbasedstereotacticbodyradiotherapysbrtinthetreatmentofuncomplicatednonspinalboneoligometastasesfromprostatecancer AT ruggeroruggieri psmapetctbasedstereotacticbodyradiotherapysbrtinthetreatmentofuncomplicatednonspinalboneoligometastasesfromprostatecancer AT filippoalongi psmapetctbasedstereotacticbodyradiotherapysbrtinthetreatmentofuncomplicatednonspinalboneoligometastasesfromprostatecancer |